Followers | 275 |
Posts | 56301 |
Boards Moderated | 24 |
Alias Born | 08/29/2007 |
Saturday, July 13, 2024 5:02:29 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent LLY News
- Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium • PR Newswire (US) • 11/01/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2024 08:17:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 03:54:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 11:05:55 AM
- Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products • PR Newswire (US) • 10/30/2024 10:45:00 AM
- US Futures Rise as Tech Earnings Drive Market Optimism; Oil Prices Edge Up • IH Market News • 10/30/2024 10:37:30 AM
- Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study • PR Newswire (US) • 10/29/2024 04:15:00 PM
- Lilly declares fourth-quarter 2024 dividend • PR Newswire (US) • 10/28/2024 03:31:00 PM
- Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease • PR Newswire (US) • 10/28/2024 10:45:00 AM
- Philips Sales Forecast Cut Sparks Stock Plunge; BP Resumes Libya Exploration; Alibaba Settles for $433 Million • IH Market News • 10/28/2024 10:09:33 AM
- Lilly's EBGLYSS™ (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab • PR Newswire (US) • 10/25/2024 10:45:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 10/23/2024 09:17:34 PM
- Lilly's Kisunla™ (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E Ε4 Heterozygotes or Non-Carriers • PR Newswire (US) • 10/23/2024 09:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:22:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:20:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:18:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/22/2024 08:16:12 PM
- HSBC Begins Major Restructuring; SAP’s Cloud Revenue Grows 25%; Logitech Shares Drop 7.3% Pre-Market • IH Market News • 10/22/2024 10:04:11 AM
- Lilly confirms date and conference call for third-quarter 2024 financial results announcement • PR Newswire (US) • 10/16/2024 02:00:00 PM
- Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies • PR Newswire (US) • 10/16/2024 11:30:00 AM
- Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease • PR Newswire (US) • 10/14/2024 10:45:00 AM
- Tesla’s Robotaxi Day; GSK Settles 93% of Zantac Lawsuits; 10x Genomics Stock Drops on Revenue Forecast • IH Market News • 10/10/2024 10:45:48 AM
- Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • InvestorsHub NewsWire • 10/02/2024 01:00:00 PM
- Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials • PR Newswire (US) • 10/02/2024 11:30:00 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM